Stock-Based Compensation | Note 9—Stock-Based Compensation For the three months ended June 30, 2018 and 2017, the Company’s income before income taxes was reduced for stock-based compensation expense of $13.3 and $12.3, respectively. In addition, for the three months ended June 30, 2018 and 2017, the Company recognized aggregate income tax benefits associated with stock-based compensation of $4.9 and $24.1, respectively, in the provision for income taxes in the accompanying Condensed Consolidated Statements of Income, which include the excess tax benefits from option exercises of $3.0 (or $0.01 per share) and $21.2 (or $0.07 per share), respectively. For the six months ended June 30, 2018 and 2017, the Company’s income before income taxes was reduced for stock-based compensation expense of $26.0 and $24.4, respectively. In addition, for the six months ended June 30, 2018 and 2017, the Company recognized aggregate income tax benefits associated with stock-based compensation of $10.8 and $35.1, respectively, which include the excess tax benefits from option exercises of $7.1 (or $0.02 per share) and $29.2 (or $0.09 per share), respectively. T he impact associated with recognizing excess tax benefits from option exercises in the provision for income taxes on our consolidated financial statements could result in significant fluctuations in our effective tax rate in the future, since the provision for income taxes will be impacted by the timing and intrinsic value of future stock-based compensation award exercises. Stock-based compensation expense includes the estimated effects of forfeitures, which are adjusted over the requisite service period to the extent actual forfeitures differ or are expected to differ from such estimates. Changes in estimated forfeitures are recognized in the period of change and impact the amount of expense to be recognized in future periods. The expense incurred for stock-based compensation plans is included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Income. Stock Options In May 2017, the Company adopted the 2017 Stock Purchase and Option Plan for Key Employees of Amphenol and Subsidiaries (the “2017 Employee Option Plan”). A committee of the Company’s Board of Directors has been authorized to grant stock options pursuant to the 2017 Employee Option Plan. The number of shares of the Company’s Class A Common Stock (“Common Stock”) reserved for issuance under the 2017 Employee Option Plan is 30,000,000 shares. As of June 30, 2018, there were 16,947,280 shares of Common Stock available for the granting of additional stock options under the 2017 Employee Option Plan. The Company also continues to maintain the 2009 Stock Purchase and Option Plan for Key Employees of Amphenol and Subsidiaries, as amended (the “2009 Employee Option Plan”). No additional stock options will be granted under the 2009 Employee Option Plan. The 2000 Stock Purchase and Option Plan for Key Employees of Amphenol and Subsidiaries, as amended, expired in May 2011 and all options granted thereunder have been either exercised or forfeited. Options granted under the 2017 Employee Option Plan and the 2009 Employee Option Plan generally vest ratably over a period of five years from the date of grant and are generally exercisable over a period of ten years from the date of grant. In 2004, the Company adopted the 2004 Stock Option Plan for Directors of Amphenol Corporation (the “2004 Directors Option Plan”). The 2004 Directors Option Plan is administered by the Company’s Board of Directors. The 2004 Directors Option Plan expired in May 2014, except that its terms continue with respect to outstanding options granted thereunder. Options were last granted under the 2004 Directors Option Plan in May 2011. Options granted under the 2004 Directors Option Plan are fully vested and are generally exercisable over a period of ten years from the date of grant. Stock option activity for the three and six months ended June 30, 2018 was as follows: Weighted Average Aggregate Weighted Remaining Intrinsic Average Contractual Value Options Exercise Price Term (in years) (in millions) Options outstanding at January 1, 2018 33,222,364 $ 52.27 7.05 $ 1,180.3 Options granted — Options exercised (602,549) Options forfeited (32,240) Options outstanding at March 31, 2018 32,587,575 52.58 6.84 1,093.2 Options granted 6,111,100 Options exercised (740,046) Options forfeited (116,740) Options outstanding at June 30, 2018 37,841,889 $ 58.50 7.15 $ 1,089.4 Vested and non-vested options expected to vest at June 30, 2018 35,378,287 $ 57.63 7.06 $ 1,048.7 Exercisable options at June 30, 2018 18,269,909 $ 45.14 5.65 $ 767.5 A summary of the status of the Company’s non-vested options as of June 30, 2018 and changes during the three and six months then ended is as follows: Weighted Average Fair Value at Options Grant Date Non-vested options at January 1, 2018 19,600,440 $ 8.29 Options granted — — Options vested (67,400) 8.13 Options forfeited (32,240) 8.56 Non-vested options at March 31, 2018 19,500,800 8.29 Options granted 6,111,100 12.82 Options vested (5,923,180) 8.35 Options forfeited (116,740) 8.18 Non-vested options at June 30, 2018 19,571,980 $ 9.69 During the three and six months ended June 30, 2018 and 2017, the following activity occurred under the Company’s option plans: Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Total intrinsic value of stock options exercised $ 35.1 $ 79.6 $ 69.4 $ 114.1 Total fair value of stock options vested 49.5 44.8 50.0 45.5 As of June 30, 2018, the total compensation cost related to non-vested options not yet recognized was approximately $165.9 with a weighted average expected amortization period of 3.75 years. The grant-date fair value of each option grant under the 2009 Employee Option Plan, the 2017 Employee Option Plan and the 2004 Directors Option Plan is estimated using the Black-Scholes option pricing model. The grant-date fair value of each share grant is determined based on the closing share price of the Company’s Common Stock on the date of the grant. The fair value is then amortized on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Use of a valuation model for option grants requires management to make certain assumptions with respect to selected model inputs. Expected share price volatility is calculated based on the historical volatility of the Common Stock and implied volatility derived from related exchange traded options. The average expected life is based on the contractual term of the option and expected exercise and historical post-vesting termination experience. The risk-free interest rate is based on U.S. Treasury zero-coupon issuances with a remaining term equal to the expected life assumed at the date of grant. The expected annual dividend per share is based on the Company’s dividend rate. Restricted Shares In 2012, the Company adopted the 2012 Restricted Stock Plan for Directors of Amphenol Corporation (the “2012 Directors Restricted Stock Plan”). The 2012 Directors Restricted Stock Plan is administered by the Company’s Board of Directors. As of June 30, 2018, the number of restricted shares available for grant under the 2012 Directors Restricted Stock Plan was 109,695. Restricted shares granted under the 2012 Directors Restricted Stock Plan generally vest on the first anniversary of the grant date. Grants under the 2012 Directors Restricted Stock Plan entitle the holder to receive shares of the Company’s Common Stock without payment. Restricted share activity for the three and six months ended June 30, 2018 was as follows: Weighted Average Remaining Restricted Fair Value at Amortization Shares Grant Date Term (in years) Restricted shares outstanding at January 1, 2018 12,905 $ 73.25 0.37 Restricted shares granted — — Restricted shares outstanding at March 31, 2018 12,905 73.25 0.13 Shares vested and issued (13,046) 73.35 Restricted shares granted 14,469 87.93 Restricted shares outstanding at June 30, 2018 14,328 $ 87.98 0.88 As of June 30, 2018, the total compensation cost related to non-vested restricted shares not yet recognized was approximately $1.1 with a weighted average expected amortization period of 0.88 years. |